



SVB Securities Serves as Exclusive Financial Advisor to Asceneuron on its Licensing Agreement with Ferrer for ASN90 for the Treatment of Progressive Supranuclear Palsy (PSP)

Key Transaction Highlights

- On February 22, 2023, Asceneuron SA (“Asceneuron”) and Ferrer Internacional SA (“Ferrer”) announced the signing of a licensing agreement in which Ferrer obtains the exclusive worldwide rights to develop and commercialize ASN90 in progressive supranuclear palsy (PSP), an orphan, tau-related disease with a high unmet medical need.
- Ferrer will now conduct a Phase II clinical study to determine the efficacy and optimal dose range of ASN90.
- Asceneuron will receive an upfront fee and multiple development, regulatory and commercial milestone payments. Asceneuron is also eligible to receive tiered double-digit royalties on worldwide net sales of ASN90.
- SVB Securities acted as exclusive financial advisor to Asceneuron.

About Asceneuron

Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need. The pipeline reflects their ambition to develop treatments for a wide a range of neurodegenerative diseases including orphan tauopathies, Alzheimer’s and Parkinson’s disease. Asceneuron has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including one first in class for Parkinson’s disease, one best in class in Alzheimer’s disease and related disorders.

About Ferrer

Ferrer is a privately-held biopharmaceutical company dedicated to making a positive impact in society. Founded in Barcelona in 1959, the company is currently present in more than a hundred countries and has a team of over 1,800 people. Ferrer’s experience and knowledge make a difference in five treatment areas: pulmonary hypertension, the nervous system, pain, cardiometabolism, gastroenterology and dermatology. In these areas, Ferrer offers trusted products that meet the highest European quality standards. It manufactures many of these products itself.

If you would like to unsubscribe from this distribution, click [here](#). If you would like to unsubscribe from all SVB Securities distributions, click [here](#).

THIS EMAIL IS FOR INFORMATIONAL PURPOSES ONLY AND IS BEING FURNISHED TO INVESTMENT BANKING CLIENTS OF SVB SECURITIES LLC. THE INFORMATION INCLUDED HEREIN IS FOR YOUR INFORMATION ONLY AND MAY NOT BE REPRODUCED FOR OR REDISTRIBUTED TO ANY OTHER PURPOSES. THIS EMAIL IS NOT AN OFFER TO SELL, AND IS NOT SOLICITING AN OFFER TO BUY, ANY SECURITIES.

BOSTON
53 State Street
40th Floor
Boston, MA 02109

CHARLOTTE
2151 Hawkins Street
Suite 1025
Charlotte, NC 28203

NASHVILLE
40 Burton Hills Boulevard
Suite 200
Nashville, TN 37215

NEW YORK
1301 Avenue of the Americas
12th Floor
New York, NY 10019

SAN FRANCISCO
255 California Street
12th Floor
San Francisco, CA 94111